Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)

Market Cap	5.09B -21.4%
Revenue (ttm)	1.20B -0.1%
Net Income	183.06M -27.2%
EPS	0.81 -27.1%
Shares Out	226.80M
PE Ratio	27.81
Forward PE	26.10
Dividend	0.20 (1.01%)
Ex-Dividend Date	May 27, 2026

Volume	3,673,539
Open	22.97
Previous Close	22.45
Day's Range	21.48 - 22.97
52-Week Range	18.57 - 33.79
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About SHE:002880

Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1985
• Employees: 901
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002880

Financial Performance

In 2025, SHE:002880's revenue was 1.27 billion, an increase of 5.28% compared to the previous year's 1.20 billion. Earnings were 246.32 million, a decrease of -2.84%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error